BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript

BioCardia reported a Q2 2025 net loss of $2.0 million, up from $1.6 million year-over-year, driven by increased R&D as it advances its pipeline. The company is prioritizing regulatory submissions for its CardiAMP Heart Failure therapy (BCDA-01), which demonstrated a statistically significant composite endpoint benefit (p=0.02) in patients with elevated NT-proBNP, with Q4 2025 meetings anticipated with Japan's PMDA and the FDA for potential market entry. Concurrently, BioCardia plans a Q3 2025 FDA submission for its Helix biotherapeutic delivery system and seeks non-dilutive funding for its CardiALLO program by Q1 2026, while actively pursuing partnerships across its platforms. With a cash position of $1.1 million providing runway into October, the company plans a September financing.

Analysis

BioCardia's Q2 2025 results signal a strategic pivot from clinical trial execution towards securing regulatory approval for its lead asset, CardiAMP cell therapy (BCDA-01), in heart failure. The investment case hinges on the strength of a subgroup analysis from its pivotal trial, which, despite missing the primary endpoint for the overall population (p=0.17), demonstrated a statistically significant composite benefit in patients with elevated NT-proBNP (p=0.02). The company is leveraging this data to engage with Japan's PMDA and the US FDA in Q4 2025, with a particularly strong narrative for the Japanese market due to cultural preferences for autologous therapies and a significant unmet need. Financially, the company's position is precarious; the net loss widened to $2.0 million from $1.6 million year-over-year, and its current cash of $1.1 million provides runway only into October 2025. This necessitates a financing planned for September, creating a significant overhang and dilution risk for current shareholders. While the company maintains a low annual cash burn of approximately $6 million and is pursuing value-creating partnerships for its platform technologies like Helix and Morph DNA, its immediate future is tied to successfully navigating the upcoming financing and subsequent regulatory discussions.

Key Decisions for Investors

• Investors should focus on the outcomes of the planned Q4 2025 meetings with Japan's PMDA and the US FDA, as a clear pathway to submission for CardiAMP would be a primary de-risking event and a significant stock catalyst.
• The confirmed September financing presents a critical near-term risk; its terms will reveal the level of investor confidence and determine the extent of shareholder dilution required to fund operations through key regulatory milestones.
• The investment thesis rests on regulators accepting a marketing application based on a subgroup analysis, which carries inherent risk, and investors should consider the potential for agencies to require completion of the CardiAMP Heart Failure II trial before approval.
• Monitor for progress on the Q3 2025 FDA submission for the Helix delivery system and any partnership announcements for the platform technologies, as these could provide non-dilutive capital and serve as important validation ahead of the main therapeutic decisions.